[Corrigendum] Zoledronic acid sensitizes breast cancer cells to fulvestrant via ERK/HIF‑1 pathway inhibition in vivo.

A corrigendum was issued for an article published in Molecular Medicine Reports, acknowledging inadvertent errors in the use of images in the original publication. The authors corrected the figures to accurately represent the data, with the Editor's approval. The study focused on the sensitization of breast cancer cells to fulvestrant by zoledronic acid via ERK/HIF-1 pathway inhibition in vivo, with no major conclusions altered by the errors. The authors expressed regret for any inconvenience caused and thanked the Editor for the opportunity to publish the corrigendum. [Extracted from the article]